Monitor whether GCTK maintains Nasdaq's $1.00 minimum bid price through the November 9, 2026 deadline. The company's cash runway is extremely limited (~$1.12M pre-offering) and the $2.85M net proceeds will be partially consumed by debt repayment. Watch for further dilutive financings or potential delisting if the stock price falls below $1.00.
Price Chart
Executive Summary
Glucotrack is conducting a registered direct offering of 169,388 shares of common stock and 1,350,220 pre-funded warrants at $2.04 per share, raising approximately $2.85 million in net proceeds. The company has a going concern qualification, an accumulated deficit of $159 million, and faces Nasdaq delisting risk if it fails to maintain a $1.00 bid price through November 9, 2026. Proceeds will be used to repay ~$1.34 million of bridge notes and for general corporate purposes.
Key Facts
- Offering of 169,388 shares and 1,350,220 pre-funded warrants at $2.04 per share, gross proceeds $3.1 million, net ~$2.85 million
- As of June 30, 2026, accumulated deficit of $159 million and cash of only $1.12 million
- Going concern qualification from independent auditor; pro forma net tangible book value per share of $(14.48) after offering
- Nasdaq conditional listing extension requires maintaining $1.00 bid price through November 9, 2026; prior delisting notices for bid price and equity deficiencies
- Net proceeds of ~$2.85 million to be used to repay ~$1.34 million of Bridge Notes (8% interest, due April 2027) and for working capital
- Outstanding convertible notes, warrants, and preferred stock represent massive potential dilution: 4.6M shares from preferred conversion, all shares from Bridge Notes/Warrants, 4.8M September Warrants, and 355,556 PIPE Warrants
- Company has no revenue and is a pre-commercial medical device/biopharma entity with two clinical-stage subsidiaries
Financial Impact
Dilutive offering of $3.1M gross ($2.85M net) at $2.04/share; pro forma net tangible book value per share of $(14.48); immediate dilution of $16.52 per share for new investors
Risk Factors
- Nasdaq delisting risk if bid price falls below $1.00 before November 9, 2026
- Going concern risk with only $1.12M cash pre-offering and $159M accumulated deficit
- Massive dilution from outstanding convertible notes, warrants, and preferred stock
- Pre-revenue status with no approved products and uncertain clinical timelines
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-044192 |
| Document: 0001493152-26-044192-index-headers.html | 0001493152-26-044192 |
| Document: 0001493152-26-044192-index.html | 0001493152-26-044192 |
| Document: 0001493152-26-044192.txt | 0001493152-26-044192 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $0.4032 | awaiting T+60 | — | $1.71 (−324.11%) |
Oct 19, 2026 8d ago | 8-K | $0.6511 | awaiting T+60 | — | $1.71 (+162.63%) |
Oct 13, 2026 14d ago | S-1/A | $0.8873 | awaiting T+60 | — | $1.71 (−92.72%) |
Oct 13, 2026 14d ago | 425 | $0.8873 | awaiting T+60 | — | $1.71 (+92.72%) |
Sep 28, 2026 29d ago | 8-K | $1.74 | awaiting T+60 | — | $1.71 (−1.72%) |
Sep 24, 2026 4w ago | 424B5 | $1.82 | awaiting T+60 | — | $1.71 (+6.04%) |
Sep 24, 2026 4w ago | 8-K | $1.82 | awaiting T+60 | — | $1.71 (+6.04%) |
Sep 23, 2026 4w ago | 425 | $2.03 | awaiting T+60 | — | $1.71 (−15.76%) |
Sep 23, 2026 4w ago | 8-K | $2.03 | awaiting T+60 | — | $1.71 (−15.76%) |
Sep 18, 2026 5w ago | 8-K | $2.30 | awaiting T+60 | — | $1.71 (−25.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers